ReviewJournal of geriatric oncology2020
Management of bladder cancer in older patients: Position paper of a SIOG Task Force.
Review in Journal of geriatric oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Comparison of Health-Related Quality of Life Between Ileal Conduit Diversion and Orthotopic Neobladder in Women: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma.Bladder cancer (Amsterdam, Netherlands) · 2022Pooled it
- Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.World journal of urology · 2021Pooled it
- Surgery in Older Cancer Patients.Current oncology reports · 2026Review
- Frailty and Oncology: An Increasingly Common Combination.Cancer medicine · 2026Review
- FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer.Cell death & disease · 2025Article
- Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle-Invasive Bladder Cancer in the United States.Cancer medicine · 2025Article
- Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer.Insights into imaging · 2025Article
- The Global RAdical Cystectomy Evaluation and Management (GRACEM) pathway: single-centre prospective observational cohort study protocol.BJUI compass · 2025Article
- Evaluating the Survival Benefits of Perioperative Chemotherapy in Frail and Morbid Muscle-Invasive Bladder Cancer Patients.Journal of personalized medicine · 2024Article
- Complete retroperitoneal cutaneous ureterostomy with robot-assisted radical cystectomy.IJU case reports · 2024Article
- The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence.Frontiers in oncology · 2024Article
- One-Year Follow-Up after Multimodal Prehabilitation Interventions in Radical Cystectomy.Cancers · 2023Article
- Additional Value of Mini-Cog© in Urogeriatric Patients Concurrently Screened by G8 Scores.Medicines (Basel, Switzerland) · 2023Article
- Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review.Journal of clinical medicine · 2023Review
- Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.Cancers · 2022Review
- Incidence, prognostic factors and survival in bladder cancer patients: a population-based study.Translational cancer research · 2022Article
- From fast-track to enhanced recovery after surgery in radical cystectomy pathways: A nursing perspective.Asia-Pacific journal of oncology nursing · 2022Review
- Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?Drugs & aging · 2022Review
Corrections and comments
- Commented on byGeriatrics.2021
Authors and funding
12 authors at 11 institutions in 9 countries.
Funding
Abstract
Median age at bladder cancer (BC) diagnosis is older than for other major tumours. Age should not determine treatment, and patients should be fully involved in decisions. Patients should be screened with Mini-Cog™ for cognitive impairment and the G8 to ascertain need for comprehensive geriatric assessment. In non-muscle invasive disease, older adult patients should have standard therapy. Age does not contraindicate intravesical therapy. Independent of age and fitness, patients with muscle-invasive BC should have at least cross-sectional imaging. Data suggest extensive undertreatment in older adult patients, leading to poor outcomes. Standard treatment for a fit patient differs between countries. Radical cystectomy and trimodality therapy are first-line options. Radical cystectomy patients should be referred to an experienced centre and prehabilitation is mandatory. Older adult patients should be considered for neoadjuvant and adjuvant therapy, according to guidelines. In urinary diversion, avoiding bowel surgery for reconstruction of the lower urinary tract significantly reduces complications. If a patient is unfit for or refuses standard treatment, RT alone, or TURBT in selected cases should be considered. In metastatic BC, older adult patients should receive standard systemic therapy, depending on fitness for cisplatin and prognosis. Efficacy and tolerability of immunotherapy (IO) appears similar to younger patients. Second line IO is standard in platinum pre-treated patients, with benefit and tolerability in the older adult similar to younger patients. The toxicity profile seems to favour IO in the older adult but more data are needed. Patients progressing on IO may respond to further systemic treatment. In metastatic disease, palliative care should begin early.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.